Redpin Therapeutics is a privately-held, preclinical stage gene therapy company based in New York City.  We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy.

Pharmaceutical

Redpin Therapeutics

Elma S. Hawkins

Scott Jeffers

David Bleakman

The team that would go on to found Redpin Therapeutics had a wealth of experience in the biotech industry. The Executive Chairman had previously been with Quiet Therapeutics, while the President and CEO came from Lion Biotechnologies. The Founder and CEO was also the COO and Vice Chairman at Antigenics. All three members of the team had significant experience in founding and running biotech companies, as well as holding various leadership positions within the industry.

Founding Team

About

Team members

Other teams at Redpin Therapeutics

CEO and Executive Team

Leadership Team